6414 related articles for article (PubMed ID: 21809660)
21. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
22. Combination chemotherapy with dacarbazine and lomustine in disseminated malignant melanoma.
Joensuu H; Asola R; Minn H
Acta Radiol Oncol; 1986; 25(3):177-9. PubMed ID: 3020881
[TBL] [Abstract][Full Text] [Related]
23. Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma.
Cohen SM; Ohnuma T; Ambinder EP; Holland JF
Cancer Treat Rep; 1986 May; 70(5):688-9. PubMed ID: 2423239
[No Abstract] [Full Text] [Related]
24. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
Robert C; Dummer R; Gutzmer R; Lorigan P; Kim KB; Nyakas M; Arance A; Liszkay G; Schadendorf D; Cantarini M; Spencer S; Middleton MR
Lancet Oncol; 2013 Jul; 14(8):733-40. PubMed ID: 23735514
[TBL] [Abstract][Full Text] [Related]
25. Mismatch repair and treatment resistance in ovarian cancer.
Helleman J; van Staveren IL; Dinjens WN; van Kuijk PF; Ritstier K; Ewing PC; van der Burg ME; Stoter G; Berns EM
BMC Cancer; 2006 Jul; 6():201. PubMed ID: 16879751
[TBL] [Abstract][Full Text] [Related]
26. Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas.
de Jong RA; Boerma A; Boezen HM; Mourits MJ; Hollema H; Nijman HW
Int J Cancer; 2012 Oct; 131(8):1828-36. PubMed ID: 22287095
[TBL] [Abstract][Full Text] [Related]
27. [Chemotherapy of malignant melanoma].
Avril MF
Ann Dermatol Venereol; 1988; 115(9):959-68. PubMed ID: 2464963
[No Abstract] [Full Text] [Related]
28. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
29. Biallelic somatic inactivation of the mismatch repair gene MLH1 in a primary skin melanoma.
Castiglia D; Pagani E; Alvino E; Vernole P; Marra G; Cannavò E; Jiricny J; Zambruno G; D'Atri S
Genes Chromosomes Cancer; 2003 Jun; 37(2):165-75. PubMed ID: 12696065
[TBL] [Abstract][Full Text] [Related]
30. Temozolomide and cisplatin in avdanced malignant melanoma.
Daponte A; Ascierto PA; Gravina A; Melucci M; Scala S; Ottaiano A; Simeone E; Palmieris G; Comella G
Anticancer Res; 2005; 25(2B):1441-7. PubMed ID: 15865103
[TBL] [Abstract][Full Text] [Related]
31. Combined chemotherapy with or without interferon alpha N1 (IFN) for advanced malignant melanoma--a randomized pilot phase III study.
Gorbonova VA; Egorov GN; Perevodchikova NI; Orel NF
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():310-4. PubMed ID: 10939991
[No Abstract] [Full Text] [Related]
32. Circumventing melanoma chemoresistance by targeting DNA repair.
Mocellin S; Bertazza L; Benna C; Pilati P
Curr Med Chem; 2012; 19(23):3893-9. PubMed ID: 22788765
[TBL] [Abstract][Full Text] [Related]
33. The prognostic role of CD4+ and CD8+ lymphocytes during chemoimmunotherapy in metastatic melanoma.
Hernberg MM; Hahka-Kemppinen MH; Pyrhönen SO
Melanoma Res; 2004 Dec; 14(6):493-500. PubMed ID: 15577320
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
Tan EH; Ang PT
Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical staining for mismatch repair proteins, and its relevance in the diagnosis of hereditary non-polyposis colorectal cancer.
Ewald J; Rodrigue CM; Mourra N; Lefèvre JH; Fléjou JF; Tiret E; Gespach C; Parc YR
Br J Surg; 2007 Aug; 94(8):1020-7. PubMed ID: 17440950
[TBL] [Abstract][Full Text] [Related]
36. Reduced MLH1 expression after chemotherapy is an indicator for poor prognosis in esophageal cancers.
Kishi K; Doki Y; Yano M; Yasuda T; Fujiwara Y; Takiguchi S; Kim S; Higuchi I; Monden M
Clin Cancer Res; 2003 Oct; 9(12):4368-75. PubMed ID: 14555508
[TBL] [Abstract][Full Text] [Related]
37. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.
Nakai K; Mitomi H; Alkam Y; Arakawa A; Yao T; Tokuda E; Saito M; Kasumi F
Cancer Chemother Pharmacol; 2012 Apr; 69(4):923-30. PubMed ID: 22083523
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
39. Reduced host cell reactivation of oxidative DNA damage in human cells deficient in the mismatch repair gene hMSH2.
Pitsikas P; Lee D; Rainbow AJ
Mutagenesis; 2007 May; 22(3):235-43. PubMed ID: 17351251
[TBL] [Abstract][Full Text] [Related]
40. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine.
Planck M; Ericson K; Piotrowska Z; Halvarsson B; Rambech E; Nilbert M
Cancer; 2003 Mar; 97(6):1551-7. PubMed ID: 12627520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
